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SynchrotronMultifunctional enzyme type 2 (MFE-2) forms part of the fatty acid b-oxidation pathway in peroxi-
somes. MFE-2s from various species reveal proteins with structurally homologous functional
domains assembled in different compilations. Crystal structures of all domain types are known.
SAXS data from human, fruit ﬂy and Caenorhabditis elegans MFE-2s and their constituent domains
were collected, and both ab initio and rigid body models constructed. Location of the putative sub-
strate binding helper domain SCP-2L (sterol carrier protein 2-like), which is not part of MFE-2 pro-
tein in every species and not seen as part of any previous MFE-2 structures, was determined. The
obtained models of human and C. elegans MFE-2 lend a direct structural support to the idea of
the biological role of SCP-2L.
Structured summary of protein interactions:
HsMFE-2 and HsMFE-2 bind by x ray scattering (View interaction)
CeMFE-2 and CeMFE-2 bind by x ray scattering (View interaction)
DmMFE-2 and DmMFE-2 bind by x ray scattering (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Multifunctional enzyme type 2 (MFE-2) is a ubiquitous eukary-
otic peroxisomal fatty acid metabolizing protein carrying, in the
same polypeptide, two out of four enzymatic activities of the
b-oxidation spiral [1,2]. In humans both activities of MFE-2, the
3R-hydroxyacyl-CoA dehydrogenase (‘‘dehydrogenase, DH’’) and
the 2E-enoyl-CoA hydratase 2 (‘‘hydratase 2, H2’’), are indispens-
able, since a metabolic accumulation disease (D-bifunctionalprotein (D-BP) deﬁciency) follows from diminished function of
either activities [3]. In addition to the enzymatic domains verte-
brate and zebraﬁsh MFE-2s have an additional domain, which is
homologous and structurally very similar to the unspeciﬁc lipid-
binding protein sterol carrier protein 2 (SCP-2), and therefore usu-
ally referred to as SCP-2L (-like) domain [4,5]. Crystal or NMR
structures of all these domains as stand-alone proteins have been
solved and structure–function relationships concerning e.g. dimer-
ization, substrate speciﬁcity and genotype–phenotype correlation
in the D-BP deﬁciency have been studied [6–13].
Genetic and protein studies have revealed that MFE-2 proteins
from different species have been compiled from the above func-
tional domains in different ways (Fig. 1). In the MFE-2 sequence
the dehydrogenase domain is always N-terminal, followed by the
hydratase 2 and the SCP-2L domains with notable exceptions: (i)
Drosophila melanogaster and most yeasts represent species devoid
of SCP-2L domain, (ii) yeasts have a duplicated dehydrogenase
domain preceding the hydratase 2 [14], and (iii) Caenorhabditis
elegans dehydrogenase forms a fusion protein with the SCP-2L
domain while expressing the hydratase 2 as a separate
Fig. 1. Domain composition of MFE-2 proteins from human, D. melanogaster and C. elegans. The domain names dehydrogenase, hydratase 2 and SCP-2L stand for 3R-
hydroxyacyl-CoA dehydrogenase, 2E-enoyl-CoA hydratase 2 and sterol carrier protein 2-like, respectively. For clarity, N- and C-termini, connecting loop regions as well as the
domains are not in scale. As discussed in the text, the connecting loop between the dehydrogenase and the hydratase 2 domains in the human MFE-2 is considerably longer
than in the Drosophila protein. The loops separating the SCP-2L domain from the nearest enzymatic domain are of comparable length in the human and the C. elegans proteins.
aa = amino acid.
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mains in various MFE-2s is known from the crystal structure of
the D. melanogaster protein (DmMFE-2) [15] it is not known how
the SCP-2L domain complements the structural assembly of SCP-
2L-containing MFE-2s.
Why do some MFE-2s possess the SCP-2L domain and some
others not? Various studies have shown that SCP-2 or SCP-2L do-
main binds lipids that are known to be substrates for MFE-2, such
as long-chain [16] and very long-chain [17] saturated and unsatu-
rated [18] fatty acyl-CoAs and C27-intermediates of bile acid syn-
thesis [19], but they also bind lipids that are not, or not known to
be, substrates of MFE-2: free fatty acids [20], phytanoyl-CoA [21],
16-doxylstearic acid [6] and Triton X-100 [8]. The suggested func-
tion of SCP-2/SCP-2L is mostly a trafﬁcking/uptake protein carrying
lipids between membranes and other lipid-containing cellular ob-
jects or a substrate-binding helper domain. Concerning D-BP deﬁ-
ciency in humans, there are no known mutations in the SCP-2L
domain that would be responsible for the disease, indicating that
either such cases go undetected or that e.g. a point mutation is
not enough to impede substrate binding to a generous hydropho-
bic binding pocket of SCP-2L. On the other hand mice lacking
SCP-2 display disrupted cholesterol and biliary lipid metabolism
[22] and branched-chain fatty acyl-CoA catabolism [21] indicative
of SCP-2 deﬁciency.
It is unlikely that the function of SCP-2L would not be connected
to the function of one or both of the enzymatic activities of MFE-2
and the question remains whether the lipid binding property of
SCP-2L contributes to function of the enzymatic domain(s). To en-
able this functionality, the SCP-2L domain would need to be posi-
tioned favorably with respect to the enzyme domain(s). In the
present work we employed SAXS to elucidate the solution struc-
tures of human (HsMFE-2), C. elegans (CeMFE-2) and Drosophila
(DmMFE-2) proteins. Their domain organization was determined
both by ab initio analysis and by hybrid modeling utilizing the
crystallographic structures of the individual MFE-2 and DmMFE-2
domains.
2. Materials and methods
2.1. Production and preparation of the samples for SAXS
measurements
The recombinant full-length DmMFE-2 and the separate DmDH
and DmH2 fragments were expressed in Eschericia coli and puriﬁed
for the SAXS data collection as previously described [15]. The
expression and puriﬁcation of the 2E-enoyl-CoA hydratase 2 frag-
ment of HsMFE-2 also followed the previously described protocol
[11]. The human SCP-2L was puriﬁed following the same protocol
as for DmH2, and the C. elegans MFE-2 was puriﬁed like the
full-length DmMFE-2 [15]. Further details of expression and
puriﬁcation of the proteins for SAXS measurements is given in
the Supplementary material.2.2. SAXS data collection and processing of the data
2.2.1. Data collection
Synchrotron X-ray scattering data were all collected at the
EMBL X33 beamline (DESY, Hamburg) [23]. The scattering patterns
of all samples were measured at several solute concentrations
ranging from 2 to 10 mg/ml. At a sample-detector distance of
2.7 m, the range of momentum transfer 0.1 < s < 5 nm1 was col-
lected. Primary data processing and evaluation of the overall struc-
tural parameters were performed using standard procedure by the
program package PRIMUS [24]. The molecular masses of the sol-
utes were evaluated by scaling against the reference solution of bo-
vine serum albumin.
2.2.2. D. melanogaster MFE-2
The dummy bead model of DmMFE-2 is an average of 10 ab ini-
tio models built from the SAXS data using the program DAMMIF
[25]. Alignment and averaging of the 10 models were done using
the programs SUPCOMB [26] and DAMAVER [27].
2.2.3. Human MFE-2
The bead model of HsMFE-2 was constructed by MONSA [28],
which simultaneously ﬁts the experimental data of DmMFE-2
and HsMFE-2 to build the two-phase model. The rigid body model
was built using the program BUNCH [29] with the crystal struc-
tures of DmMFE-2 and the SCP-2L domain of the HsMFE-2
(HsSCP-2L). DmMFE-2 and HsSCP-2L were connected to each other
using dummy residues for the missing linkers. A simulated anneal-
ing protocol was used to ﬁnd an interconnected conﬁguration with
no steric clashes that produces the best ﬁt to the experimental
data.
2.2.4. C. elegans MFE-2
Experimental data of the dehydrogenase domain of CeMFE-2
(CeDH) and CeMFE-2 were simultaneously ﬁtted by the program
MONSA [28] to build the multiphase bead model. The program
BUNCH [29] uses CeDH and HsSCP2-L domains to ﬁt CeMFE-2
experimental data and build the rigid body model.
3. Results
3.1. D. melanogaster MFE-2
The crystal structure of DmMFE-2 is known at 2.15 Å resolution
[15]. It forms a compact ‘double dimeric’ structure in which both
the dehydrogenase and the hydratase 2 from different MFE-2
monomers form dimers (Fig. 2). SAXS structure of DmMFE-2 and
its ﬁt with the crystal structure would indicate the value of using
DmMFE-2 as a framework for the human protein, which in addition
contains the SCP-2L domain in each MFE-2 monomer. SAXS data
were collected from the full-length DmMFE-2, the dehydrogenase
domain (DmDH), the hydratase 2 domain (DmH2) and the two
Fig. 2. Ab initio model of D. melanogaster MFE-2 (DmMFE-2). (a) SAXS model of DmMFE-2 superimposed with its crystal structure. The ab initio model is presented in white,
crystal structures of dehydrogenase–hydratase monomer A in green and monomer B in blue. Dehydrogenase dimer is sited up, hydratase two dimer down. (b) As (a) but
turned 90. (c) Experimental data (dot with error bars) with the ﬁt of the ab initio model scattering pattern (in green) and the theoretical scattering pattern (in red) calculated
from the crystallographic structure using the program CRYSOL [30]. The SAXS patterns are displayed as the logarithm of the scattering intensity versus the momentum
transfer s = 4psinh/k, where k is the X-ray wavelength (1.5 Å) and 2h is the scattering angle. For clarity, only one of every 10 experimental points are represented in the ﬁgure.
M.L. Mehtälä et al. / FEBS Letters 587 (2013) 305–310 307catalytic domains together in the same solution. The calculations
done by CRYSOL [30] indicate that a DmMFE-2 monomer alone
does not ﬁt the scattering data (results not shown). This is consis-
tent with DmMFE-2 being a dimer like other MFE-2s and stand-
alone MFE-2 domains. If combined for the SAXS data collection
DmDH and DmH2 do not spontaneously assemble in vitro to form
DmMFE-2, in agreement with results from static light scattering
measurements [15].
The ab initio shape of DmMFE-2 representing the enzyme at low
resolution in solution highly resembles the overall shape from the
high resolution crystal structure of DmMFE-2. When superimpos-
ing the ab initio model of DmMFE-2 with the crystal structure
the obtained ﬁt of the two models is very good and the volume
of the particle in solution is almost completely ﬁlled (Fig. 2).
3.2. Human MFE-2
The crystal structure of the SCP-2L domain of HsMFE-2 is known
(PDB ID 1IKT), and it is known that the sequence and structural
similarities between the individual domains of MFE-2 from various
species is high. Assuming a similar structure of the catalytic do-
mains in Dm and Hs, and using the scattering curves of the full
length Dm and HsMFE-2, two models of HsMFE-2 were obtained
using alternative approaches. In one of them, a two-phase ab initio
model represents the structure as beads by ﬁtting the experimen-
tal scattering curves of Dm and HsMFE-2. Here, one phase corre-
sponds to the catalytic domains of MFE-2, which contribute toboth scattering curves. The second phase consists of the SCP-2L,
only present in the human variant. In the other approach, a rigid
body model is constructed corresponding to the conﬁguration of
the Dm catalytic domains and human SCP-2L domains that ﬁt best
the scattering pattern of HsMFE-2. The linkers missing in the PDB
ﬁles are modeled as dummy residues. As seen from the superposi-
tion in Fig. 3, the two models obtained by different methods are
consistent with each other.
The total volume, radius of gyration and Dmax are larger in the
human MFE-2 in comparison with the corresponding values from
DmMFE-2 (see Supplementary data). This was to be expected since
the Dm variant lacks the SCP-2L domain. The actual location of the
SCP-2L domains on the opposite sides of the dimer is consistent
with the fact that also the active sites of the hydratase 2 domains
are situated respectively [11]. Since the crystal structure of HsMFE-
2 is presently unknown, no direct comparison of the experimental
scattering with the theoretical scattering of the full-length protein
can be made.
3.3. C. elegans MFE-2
Crystal structures of the full length CeMFE-2 or its individual
domains are not available. The sequence homology between the
dehydrogenase and SCP-2L domains of CeMFE-2 compared with
the corresponding domains of human MFE-2 is high, allowing us
to use the same approach for SAXS structure determination as used
for DmMFE-2 and HsMFE-2. Several datasets of the C. elegans MFE-
Fig. 3. Ab initio and rigid body models of human MFE-2 (HsMFE-2). (a) A two-phase ab initio model superimposed with the rigid body model of the full length HsMFE-2. The
ab initio model depicts the catalytic domains (light grey beads) and the SCP-2L domains (dark grey beads). The dehydrogenase is displayed in pale cyan, hydratase 2 in pale
green, SCP-2L in light pink and linkers in orange. (b) As (a) but turned 90. (c) Experimental data of HsMFE-2 and DmMFE-2 with the ﬁt of the ab initio (green) and rigid body
(red) models. For clarity, the curves are offset along the logarithmic axis and only one of every 10 experimental points is represented.
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zyme (CeH2) and the two polypeptides together in the same solu-
tion (CeMFE-2 + CeH2). The two-phase ab initio model was built
using the experimental curves of CeDH and of the full length
CeMFE2, with one phase consisting of the DH domains and the
other phase the SCP-2L domains. In addition, a rigid body model
was constructed using the human dehydrogenase and SCP-2L
structures as building blocks by ﬁtting the CeMFE-2 scattering data
(Fig. 4). The linkers connecting the domains are missing in the PDB
ﬁles, and they are modeled as dummy residues. The consistency
between the superimposed ab initio and rigid body models is high,
and both models ﬁt well the experimental data of CeMFE-2. Mea-
suring the CeMFE-2 and the CeH2 together showed clearly that
these proteins do not self-assemble.
4. Discussion
Volumes and shapes of the SAXS models from different species
presented in this study provide structural envelopes with striking
similarity between the species where available constituent domain
crystal structures could be ﬁt well. This indicates high quality of
the protein samples and of the SAXS data as well as high similarity
between the static crystal structures and the potentially dynamic
low resolution solution shapes. Firstly, as expected, the shape of
the double dimeric core part of HsMFE-2 (dehydrogenase and
hydratase 2 domains) is similar to that of DmMFE-2. It is thus likely
that the formation of the dimer of the two catalytic dimers in
DmMFE-2 and HsMFE-2 is very similar despite much longer con-
necting linkers between the enzymatic domains in the latter(Fig. 1). Since the distances between the active sites remain similar
in both of these MFE-2s it is more probable that the longer linkers
in HsMFE-2 are extending outside of the compact core structure
rather than folding inside. Secondly, assembly of the SCP-2L do-
main of the two SCP-2L-containing MFE-2s (human and C. elegans)
resemble each other with the domain positioned in the vicinity of
the substrate binding pocket of the immediate enzyme domain in
spite of the fact that the enzymewhich they are connected to is dif-
ferent (Fig. 1). The crystal structures of HsDH and HsSCP-2L ﬁt well
in the volume provided by ab initio model of CeMFE-2. Despite the
revealed assembly of the full-length proteins the structural details
do not allow to draw precise conclusions regarding the direction to
which the hydrophobic pockets of the SCP-2L domains are facing.
In the SAXS models the locations of the enzyme dimers could
easily be determined, yet the low resolution does not allow to
unambiguously differentiating between the dehydrogenase dimer
and the hydratase 2 dimer. However, the locations of the SCP-2L
domains in the HsMFE-2 structure offer a solution to this problem.
The data also clearly indicate that if DmMFE-2, and CeMFE-2 are
supplemented in the SAXS data collection with the ‘‘missing do-
main’’ (i.e. SCP-2L in the case of DmMFE-2 and CeH2 in the case
of CeMFE-2) they do not assemble into heterodimers to produce
an assembly resembling human MFE-2.
Based on the present models one could speculate about possible
conformational changes upon cofactor (NAD+ for dehydrogenase)
and 3R-hydroxyacyl-CoA substrate binding. The DmMFE-2 and
the corresponding core part of HsMFE-2 are rather compact and
considerable amount of protein surface is engaged in dimerization.
DmMFE-2 and HsMFE-2 are in this respect very similar despite the
Fig. 4. Ab initio and rigid body models of C. elegans (CeMFE-2). (a) The two-phase ab initio model superimposed with the rigid body model of CeMFE-2. The color coding is as
in Fig. 3(a). (b) As (a) but turned 90. (c) Experimental data (dot with error bars) of CeDH and CeMFE2 with the ﬁts of the ab initio (green) and rigid body (red) models. For
clarity, the curves are offset along the logarithmic axis and only one of every 10 experimental points is represented.
M.L. Mehtälä et al. / FEBS Letters 587 (2013) 305–310 309aforementioned linker length difference. It could therefore be ar-
gued that the structures are rather static and large movements of
the catalytic domains are not likely (possibly limited to subtle re-
arrangements of the secondary structures or loops at entry
cavities).
The linker lengths separating the hydratase 2 domain and the
SCP-2L in HsMFE-2 and the dehydrogenase and SCP-2L domains
in CeMFE-2 are both long, above 20 amino acids (Fig. 1). This allows
us to speculate on the role of the small lipid binding domain in the
catalytic reaction(s) of HsMFE-2. In theory, the length of the linker
may allow the SCP-2L domain to shuttle between the catalytic do-
mains. In this sense the role of SCP-2L domain could simply be aux-
iliary by ﬁshing bulky and poorly water soluble substrates from the
aqueous bulk and subsequently feeding them to the hydratase 2
subunit of MFE-2. After the hydration, the intermediate could, in-
stead of temporarily diffusing into the surrounding solvent, be
fetched again by SCP-2L and further presented to the dehydroge-
nase active site. In the case of CeMFE-2 the SCP-2L domain could
be a receptor receiving the substrate from the separate hydratase
2 protein. The hydrophobic pocket provided by the SCP-2L domain
is very suitable for temporary accommodation of the MFE-2 sub-
strates and the ﬂexibility provided by the connecting loop support
the idea of a role for SCP-2L in the enzymatic reactions. It remains
to be determined experimentally whether this is the case,
however.
Despite sufﬁcient amounts of pure proteins for crystallization
screenings and extensive utilization of different methods, no crys-
tals of HsMFE-2 or other SCP-2L-containing MFE-2s (CeMFE-2 and
HSDL2 (human hydroxysteroid dehydrogenase-like 2) [31]) have
been obtained (T.J.K.H. & M.L.M., unpublished results). On the con-
trary, crystallizing DmMFE-2 and several SCP-2s as stand-alone
proteins was straightforward. This may indicate that in the context
of the full length MFE-2 polypeptide the SCP-2L domain is mobile
and counter-effects crystallization. Our SAXS study did provide lowresolution structural model of SCP-2L-containing MFE-2s. The ob-
tained locations of the SCP-2L domains most likely represent an
average over the conformational space explored by the domain
and it may prove to be challenging to obtain high resolution data
about the maximum boundaries between which the SCP-2L do-
main is able to move.
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